查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1363166

美國分子診斷市場規模、佔有率和趨勢分析報告：按疾病、最終用途和細分市場預測，2023-2030 年

U.S. Molecular Diagnostics Market Size, Share & Trends Analysis Report By Disease (Healthcare-associated Infections, Respiratory), By End-use (Hospital Core Laboratory, Decentralized Test Sites), And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

美國分子診斷市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計2030年美國分子診斷市場規模將達84.6億美元，2023年至2030年年複合成長率為4.82%。

市場成長是由於人們越來越意識到實施分子診斷測試的好處，例如早期和快速檢測病毒和細菌。此外，由於醫療保健部門的成熟和有利的報銷政策而帶來的便利性預計將在預測期內推動市場成長。

此外，業內主要企業正在投資於分子診斷技術的技術進步，以開發減少人力並提供即時結果的解決方案。例如，QIAGEN 推出了用於診斷實驗室應用的 EZ2 Connect MDx 平台。該平台具有先進的自動化功能，可在 30 分鐘的周轉時間內從 24 個檢體中精製RNA 和 DNA。

快速檢測分析新興市場的開拓預計將支持市場成長。這些測試透過加快決策速度和減少分散式檢查的周轉時間，徹底改變了市場。許多公司正在開發檢測方法和分子診斷系統。用於診斷淋病奈瑟菌、沙眼衣原體的 Qiagen 的 Digene HC2 GC-ID DNA 測試和用於診斷生殖支原體並鑒定黴漿菌內酯抗藥性的Danaher (Cepheid) ResistancePlus MG FleXible 都是此類產品的範例。

雅培、西門子醫療、QIAGEN、羅氏、丹納赫、賽默飛世爾科技、Hologic Inc 和 BD 等市場主要企業正在提高基本客群。例如，2023 年 1 月，賽默飛世爾科技和阿斯特捷利康合作開發 Tagrisso 的血液和固態組織伴隨診斷測試。

COVID-19 大流行對該行業產生了積極影響，刺激了能夠檢測冠狀病毒的快速新型診斷試劑盒的開發。這導致感染疾病領域主要市場參與企業的收益增加。例如，賽默飛世爾科技 (Thermo Fisher Scientific) 報告稱，由於診斷試劑盒需求增加，2021 年 4 月收益增加了 150%。然而，該地區的疫苗普及正在取得進展，預計在預測期內對 COVID-19 檢測的需求將下降。

美國分子診斷市場報告亮點

  • 按疾病分類，2022年呼吸系統疾病領域佔據市場主導地位。這種成長是由於呼吸道感染疾病的患病不斷增加以及人們對感染疾病診斷和治療的診斷測試的可用性的認知不斷提高。
  • 按最終用途，醫院核心實驗室在 2022 年佔據最大佔有率，由於 MRSA、金黃色葡萄球菌 (SA) 和腸病毒感染疾病的患病不斷增加，在預測期內以最快的年複合成長率成長。
  • 主要行業參與者採取了各種策略，例如新產品發布、聯盟、收購和業務擴張，以提高產品滲透率並獲得更大的消費群。

目錄

第1章 調查方法和範圍

第2章 執行摘要

第3章 美國分子診斷市場變數、趨勢與範圍

  • 市場體系預測
    • 母市場預測
    • 相關/附隨市場預測
  • 普及和成長預測圖
  • 產業價值鏈分析
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 美國分子診斷市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 主要交易及策略聯盟分析
    • 打入市場策略

第4章 美國分子診斷市場：依疾病分類的預估及趨勢分析

  • 2018年至2030年市場規模、預測與趨勢分析

第5章 美國分子診斷市場：最終用途的估計與趨勢分析

  • 2018年至2030年市場規模、預測與趨勢分析

第6章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭分類
  • 供應商形勢
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 2022 年主要市場佔有率分析
    • Abbott
    • Siemens Healthcare GmbH
    • QIAGEN
    • F. Hoffmann-La Roche Ltd
    • Quest Diagnostics Incorporated
    • Danaher
    • Thermo Fisher Scientific, Inc.
    • Hologic Inc.
    • BD
    • Charles River Laboratories
    • Bio-Rad Laboratories, Inc.
    • Illumina, Inc.
    • Agilent Technologies, Inc.
Product Code: GVR-4-68040-126-4

U.S. Molecular Diagnostics Market Growth & Trends:

The U.S. molecular diagnostics market size is expected to reach USD 8.46 billion by 2030, registering a CAGR of 4.82% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market growth is attributed to increasing awareness of the benefits of adopting molecular diagnostics tests, such as early and rapid detection of viruses and bacteria. Moreover, the ease of access owing to a well-established healthcare sector coupled with favorable reimbursement policies is anticipated to drive the market growth over the forecast period.

Moreover, prominent players in the industry are investing in the technological advancement of molecular diagnostics techniques to develop solutions capable of reducing human effort and delivering instant results. For instance, QIAGEN launched the EZ2 Connect MDx platform for its application in diagnostic laboratories. The platform is equipped with a high degree of automation to purify RNA & DNA from 24 samples with a turnaround time of 30 minutes.

Developments in rapid detection assays are anticipated to support the market growth. These tests have revolutionized the market by accelerating decision-making and reducing turnaround time for decentralized testing. Numerous players are developing assays and molecular diagnostic systems. Digene HC2 GC-ID DNA test for the diagnosis of Neisseria gonorrhea, & Chlamydia trachomatis by Qiagen and ResistancePlus MG FleXible for the diagnosis of Mycoplasma genitalium with macrolide-resistance identification by Danaher Corporation (Cepheid) are examples of such products.

Major players in the market such as Abbott, Siemens Healthcare GmbH, QIAGEN, F. Hoffmann-La Roche Ltd, Danaher, Thermo Fisher Scientific, Inc., Hologic Inc., and BD, are adopting various strategies to enhance their product penetration and expand their customer base. For instance, in January 2023, Thermo Fisher Scientific and AstraZeneca entered into a collaboration to develop a blood-based and solid tissue companion diagnostic test for Tagrisso.

The COVID-19 pandemic has positively impacted the industry by encouraging players to develop rapid and novel diagnostic kits capable of detecting coronavirus. This has resulted in positive revenue growth for major market players operating in the infectious disease segment. For instance, Thermo Fisher Scientific reported 150% revenue growth owing to the rising demand for diagnostics offerings in April 2021. However, the rising adoption of vaccination in the region is anticipated to reduce the demand for COVID-19 testing over the forecast period.

U.S. Molecular Diagnostics Market Report Highlights:

  • Based on disease, the respiratory disease segment dominated the market in 2022. The growth is attributed to the increasing prevalence of respiratory infections coupled with the increasing awareness regarding the availability of diagnostic tests for diagnosing and treating infections
  • Based on end-use, the hospital core laboratory held the largest share in 2022 and is anticipated to grow at the fastest CAGR over the forecast period owing to the increasing prevalence of infections, such as MRSA, Staphylococcus aureus (SA), and enterovirus
  • Major industry players adopt different strategies such as new product launches, collaborations, acquisitions, and expansions to enhance their product penetration and gain a larger consumer base

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Disease
    • 1.1.2. End-use
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease outlook
    • 2.2.2. End-use outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Molecular Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Industry Value Chain Analysis
  • 3.4. Market Dynamics
    • 3.4.1. Market Driver Analysis
      • 3.4.1.1. Increase in geriatric population
      • 3.4.1.2. Introduction of technologically advanced products
      • 3.4.1.3. Increase in demand for point-of-care testing
      • 3.4.1.4. Growing prevalence of target diseases
      • 3.4.1.5. Increasing external funding for R&D
    • 3.4.2. Market Restraint Analysis
      • 3.4.2.1. Presence of Ambiguous Regulatory Framework
      • 3.4.2.2. High prices of molecular diagnostics tests
  • 3.5. U.S. Molecular Diagnostics Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic Landscape
    • 3.5.3. Major Deals & Strategic Alliances Analysis
    • 3.5.4. Market Entry Strategies

Chapter 4. U.S. Molecular Diagnostics Market: Disease Estimates & Trend Analysis

  • 4.1. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.1.1. Healthcare-Associated Infections
      • 4.1.1.1. Methicillin-Resistant Staphylococcus aureus
      • 4.1.1.1.1. Methicillin-Resistant Staphylococcus aureus Market Estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.1.2. Staphylococcus aureus
      • 4.1.1.2.1. Staphylococcus aureus Market Estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.1.3. Enterovirus
      • 4.1.1.3.1. Enterovirus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.1.4. Clostridioides difficile
      • 4.1.1.4.1. Clostridioides difficile market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.1.5. Van A
      • 4.1.1.5.1. Van A market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.1.6. Sepsis Panel
      • 4.1.1.6.1. Sepsis Panel market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.2. Respiratory
      • 4.1.2.1. Flu
      • 4.1.2.1.1. Flu market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.2. Respiratory Syncytial Virus
      • 4.1.2.2.1. Respiratory Syncytial Virus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.3. Paraflu
      • 4.1.2.3.1. Paraflu market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.4. Multidrug-Resistant Tuberculosis
      • 4.1.2.4.1. Multidrug-Resistant Tuberculosis market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.5. Mycobacterium Avium-Intracellular
      • 4.1.2.5.1. Mycobacterium Avium-Intracellulare market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.6. Group A Streptococcal
      • 4.1.2.6.1. Group A Streptococcal market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.7. Adenovirus
      • 4.1.2.7.1. Adenovirus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.8. Human Metapneumovirus
      • 4.1.2.8.1. Human Metapneumovirus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.9. Rhinoviruses
      • 4.1.2.9.1. Rhinoviruses market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.10. Middle East Respiratory Syndrome Coronavirus
      • 4.1.2.10.1. Middle East Respiratory Syndrome Coronavirus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.11. Tuberculosis
      • 4.1.2.11.1. Tuberculosis market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.12. Severe Acute Respiratory Syndrome Coronavirus 2
      • 4.1.2.12.1. Severe Acute Respiratory Syndrome Coronavirus 2 market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.13. Human Bocavirus-Infection
      • 4.1.2.13.1. Human Bocavirus-Infection market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.14. Bordetella
      • 4.1.2.14.1. Bordetella market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.15. Mycoplasma Pneumonia
      • 4.1.2.15.1. Mycoplasma Pneumonia market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.16. Respiratory Panels
      • 4.1.2.16.1. Respiratory Panels market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.3. Gastrointestinal
      • 4.1.3.1. Norovirus
      • 4.1.3.1.1. Norovirus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.3.2. Helicobacter pylori
      • 4.1.3.2.1. Helicobacter pylori market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.3.3. Shiga toxin
      • 4.1.3.3.1. Shiga toxin Market Estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.3.4. GI Parasite Panel
      • 4.1.3.4.1. GI Parasite Panel market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.3.5. GI Bacterial Panel
      • 4.1.3.5.1. GI Bacterial Panel market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.3.6. GI Viral Panel
      • 4.1.3.6.1. GI Viral Panel market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.3.7. GI Panels
      • 4.1.3.7.1. GI Panels market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.4. Women's Health/STI
      • 4.1.4.1. Chlamydia trachomatis (CT)/Neisseria gonorrhoeae (NG)
      • 4.1.4.1.1. Chlamydia trachomatis (CT)/Neisseria gonorrhoeae (NG) market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.2. Trichomonas Vaginalis
      • 4.1.4.2.1. Trichomonas Vaginalis market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.3. Mycoplasma Genitalium
      • 4.1.4.3.1. Mycoplasma genitalium market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.4. Human Papillomavirus
      • 4.1.4.4.1. Human Papillomavirus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.5. Bacterial Vaginosis
      • 4.1.4.5.1. Bacterial Vaginosis market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.6. Gonorrhoea Colloquially
      • 4.1.4.6.1. Gonorrhoea Colloquially market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.7. Mycoplasma Genitalium Resistance
      • 4.1.4.7.1. Mycoplasma Genitalium Resistance market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.8. Herpes Simplex Virus
      • 4.1.4.8.1. Herpes Simplex Virus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.9. Group B Streptococcus
      • 4.1.4.9.1. Group B Streptococcus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.5. Immunocompromised
      • 4.1.5.1. Cytomegalovirus
      • 4.1.5.1.1. Cytomegalovirus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.5.2. Epstein-Barr virus
      • 4.1.5.2.1. Epstein-Barr virus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.5.3. Varicella-Zoster Virus
      • 4.1.5.3.1. Varicella-Zoster Virus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.5.4. BK virus
      • 4.1.5.4.1. BK virus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.6. Virology
      • 4.1.6.1. Human immunodeficiency viruses
      • 4.1.6.1.1. Human immunodeficiency viruses market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.6.2. Hepatitis C virus
      • 4.1.6.2.1. Hepatitis C virus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.6.3. Hepatitis B virus
      • 4.1.6.3.1. Hepatitis B virus Market Estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.6.4. Hepatitis E virus
      • 4.1.6.4.1. Hepatitis E virus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.7. Other Targets
      • 4.1.7.1. Babesia
      • 4.1.7.1.1. Babesia market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.7.2. Zika
      • 4.1.7.2.1. Zika market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.7.3. West Nile Virus
      • 4.1.7.3.1. West Nile Virus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.7.4. Chikungunya virus/Dengue virus
      • 4.1.7.4.1. Chikungunya virus/Dengue Virus Market Estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.7.5. Enhancer of zeste homolog 2
      • 4.1.7.5.1. Enhancer of zeste homolog 2 market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.7.6. PIK3CA
      • 4.1.7.6.1. PIK3CA market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.7.7. Malaria
      • 4.1.7.7.1. Malaria market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.7.8. Monkeypox Virus
      • 4.1.7.8.1. Monkeypox Virus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.8. Other Panels
      • 4.1.8.1. Meningitis Panel
      • 4.1.8.1.1. Meningitis Panel market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.8.2. Lyme Panel
      • 4.1.8.2.1. Lyme Panel market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.8.3. UTI Panel
      • 4.1.8.3.1. UTI Panel market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.9. Oncology
      • 4.1.9.1. Microsatellite Instability
      • 4.1.9.1.1. Microsatellite Instability market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.9.2. B-raf
      • 4.1.9.2.1. B-raf market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.9.3. Epidermal Growth Factor Receptor
      • 4.1.9.3.1. Epidermal Growth Factor Receptor market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.9.4. Kirsten Rat Sarcoma Virus
      • 4.1.9.4.1. Kirsten Rat Sarcoma Virus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.9.5. Others
      • 4.1.9.5.1. Others Market Estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. U.S. Molecular Diagnostics Market: End-use Estimates & Trend Analysis

  • 5.1. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.1.1. Hospital Core Laboratory
      • 5.1.1.1. Hospital Core Laboratory market estimates and forecast 2018 to 2030 (USD Million)
    • 5.1.2. Hospital Alternative Sites
      • 5.1.2.1. Hospital Alternative Sites market estimates and forecast 2018 to 2030 (USD Million)
    • 5.1.3. Decentralized Test Sites
      • 5.1.3.1. Decentralized Test Site market estimates and forecast 2018 to 2030 (USD Million)
    • 5.1.4. Reference Lab
      • 5.1.4.1. Reference Lab market Estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. List of key distributors and channel partners
    • 6.3.2. Key customers
    • 6.3.3. Key Company Market Share Analysis, 2022
    • 6.3.4. Abbott
      • 6.3.4.1. Company overview
      • 6.3.4.2. Financial performance
      • 6.3.4.3. Product benchmarking
      • 6.3.4.4. Strategic initiatives
    • 6.3.5. Siemens Healthcare GmbH
      • 6.3.5.1. Company overview
      • 6.3.5.2. Financial performance
      • 6.3.5.3. Product benchmarking
      • 6.3.5.4. Strategic initiatives
    • 6.3.6. QIAGEN
      • 6.3.6.1. Company overview
      • 6.3.6.2. Financial performance
      • 6.3.6.3. Product benchmarking
      • 6.3.6.4. Strategic initiatives
    • 6.3.7. F. Hoffmann-La Roche Ltd
      • 6.3.7.1. Company overview
      • 6.3.7.2. Financial performance
      • 6.3.7.3. Product benchmarking
      • 6.3.7.4. Strategic initiatives
    • 6.3.8. Quest Diagnostics Incorporated
      • 6.3.8.1. Company overview
      • 6.3.8.2. Financial performance
      • 6.3.8.3. Product benchmarking
      • 6.3.8.4. Strategic initiatives
    • 6.3.9. Danaher
      • 6.3.9.1. Company overview
      • 6.3.9.2. Financial performance
      • 6.3.9.3. Product benchmarking
      • 6.3.9.4. Strategic initiatives
    • 6.3.10. Thermo Fisher Scientific, Inc.
      • 6.3.10.1. Company overview
      • 6.3.10.2. Financial performance
      • 6.3.10.3. Product benchmarking
      • 6.3.10.4. Strategic initiatives
    • 6.3.11. Hologic Inc.
      • 6.3.11.1. Company overview
      • 6.3.11.2. Financial performance
      • 6.3.11.3. Product benchmarking
      • 6.3.11.4. Strategic initiatives
    • 6.3.12. BD
      • 6.3.12.1. Company overview
      • 6.3.12.2. Financial performance
      • 6.3.12.3. Product benchmarking
      • 6.3.12.4. Strategic initiatives
    • 6.3.13. Charles River Laboratories
      • 6.3.13.1. Company overview
      • 6.3.13.2. Financial performance
      • 6.3.13.3. Product benchmarking
      • 6.3.13.4. Strategic initiatives
    • 6.3.14. Bio-Rad Laboratories, Inc.
      • 6.3.14.1. Company overview
      • 6.3.14.2. Financial performance
      • 6.3.14.3. Product benchmarking
      • 6.3.14.4. Strategic initiatives
    • 6.3.15. Illumina, Inc.
      • 6.3.15.1. Company Overview
      • 6.3.15.2. Financial performance
      • 6.3.15.3. Product benchmarking
      • 6.3.15.4. Strategic initiatives
    • 6.3.16. Agilent Technologies, Inc.
      • 6.3.16.1. Company Overview
      • 6.3.16.2. Financial performance
      • 6.3.16.3. Product benchmarking
      • 6.3.16.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 List of Secondary Sources
  • Table 3 U.S. Molecular Diagnostics Market, by Disease, 2018 - 2030 (USD Million)
  • Table 4 U.S. Molecular Diagnostics Market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. molecular diagnostics market: market outlook
  • Fig. 9 U.S. Molecular Diagnostics Market Competitive Insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 U.S. molecular diagnostics market driver impact
  • Fig. 15 U.S. molecular diagnostics market restraint impact
  • Fig. 16 U.S. Molecular Diagnostics Market Strategic Initiatives Analysis
  • Fig. 17 U.S. molecular diagnostics market: disease movement analysis
  • Fig. 18 U.S. molecular diagnostics market: disease outlook and key takeaways
  • Fig. 19 Methicillin-Resistant Staphylococcus aureus market estimates and forecast, 2018 - 2030
  • Fig. 20 Staphylococcus aureus market estimates and forecast, 2018 - 2030
  • Fig. 21 Enterovirus market estimates and forecast, 2018 - 2030
  • Fig. 22 Clostridioides difficile market estimates and forecast, 2018 - 2030
  • Fig. 23 Van A market estimates and forecast, 2018 - 2030
  • Fig. 24 Sepsis Panel market estimates and forecast, 2018 - 2030
  • Fig. 25 Flu market estimates and forecast, 2018 - 2030
  • Fig. 26 Respiratory Syncytial Virus market estimates and forecast, 2018 - 2030
  • Fig. 27 Paraflu market estimates and forecast, 2018 - 2030
  • Fig. 28 Multidrug-Resistant Tuberculosis market estimates and forecast, 2018 - 2030
  • Fig. 29 Mycobacterium Avium-Intracellulare market estimates and forecast, 2018 - 2030
  • Fig. 30 Group A Streptococcal market estimates and forecast, 2018 - 2030
  • Fig. 31 Adenovirus market estimates and forecast, 2018 - 2030
  • Fig. 32 Human Metapneumovirus market estimates and forecast, 2018 - 2030
  • Fig. 33 Rhinoviruses market estimates and forecast, 2018 - 2030
  • Fig. 34 Middle East Respiratory Syndrome Coronavirus market estimates and forecast, 2018 - 2030
  • Fig. 35 Tuberculosis market estimates and forecast, 2018 - 2030
  • Fig. 36 Severe Acute Respiratory Syndrome Coronavirus 2 market estimates and forecast, 2018 - 2030
  • Fig. 37 Human Bocavirus-Infection market estimates and forecast, 2018 - 2030
  • Fig. 38 Bordetella market estimates and forecast, 2018 - 2030
  • Fig. 39 Mycoplasma Pneumonia market estimates and forecast, 2018 - 2030
  • Fig. 40 Respiratory Panels market estimates and forecast, 2018 - 2030
  • Fig. 41 Norovirus market estimates and forecast, 2018 - 2030
  • Fig. 42 Helicobacter pylori market estimates and forecast, 2018 - 2030
  • Fig. 43 Shiga toxin market estimates and forecast, 2018 - 2030
  • Fig. 44 GI Parasite Panel market estimates and forecast, 2018 - 2030
  • Fig. 45 GI Bacterial Panel market estimates and forecast, 2018 - 2030
  • Fig. 46 GI Viral Panel market estimates and forecast, 2018 - 2030
  • Fig. 47 GI Panels market estimates and forecast, 2018 - 2030
  • Fig. 48 Women's Health/STI market estimates and forecast, 2018 - 2030
  • Fig. 49 Chlamydia trachomatis (CT)/Neisseria gonorrhoeae (NG) market estimates and forecast, 2018 - 2030
  • Fig. 50 Trichomonas Vaginalis market estimates and forecast, 2018 - 2030
  • Fig. 51 Mycoplasma Genitalium market estimates and forecast, 2018 - 2030
  • Fig. 52 Human Papillomavirus market estimates and forecast, 2018 - 2030
  • Fig. 53 Bacterial Vaginosis market estimates and forecast, 2018 - 2030
  • Fig. 54 Gonorrhoea Colloquially market estimates and forecast, 2018 - 2030
  • Fig. 55 Mycoplasma Genitalium Resistance market estimates and forecast, 2018 - 2030
  • Fig. 56 Herpes Simplex Virus market estimates and forecast, 2018 - 2030
  • Fig. 57 Group B Streptococcus market estimates and forecast, 2018 - 2030
  • Fig. 58 Cytomegalovirus market estimates and forecast, 2018 - 2030
  • Fig. 59 Epstein-Barr virus market estimates and forecast, 2018 - 2030
  • Fig. 60 Varicella-Zoster Virus market estimates and forecast, 2018 - 2030
  • Fig. 61 BK virus market estimates and forecast, 2018 - 2030
  • Fig. 62 Human immunodeficiency viruses market estimates and forecast, 2018 - 2030
  • Fig. 63 Hepatitis C virus market estimates and forecast, 2018 - 2030
  • Fig. 64 Hepatitis B virus market estimates and forecast, 2018 - 2030
  • Fig. 65 Hepatitis E virus market estimates and forecast, 2018 - 2030
  • Fig. 66 Babesia market estimates and forecast, 2018 - 2030
  • Fig. 67 Zika market estimates and Forecast, 2018 - 2030
  • Fig. 68 West Nile Virus market estimates and forecast, 2018 - 2030
  • Fig. 69 Chikungunya virus/dengue virus market estimates and forecast, 2018 - 2030
  • Fig. 70 Enhancer of zest homolog 2 market estimates and forecast, 2018 - 2030
  • Fig. 71 PIK3CA market estimates and forecast, 2018 - 2030
  • Fig. 72 Malaria market estimates and forecast, 2018 - 2030
  • Fig. 73 Monkeypox Virus market estimates and forecast, 2018 - 2030
  • Fig. 74 Meningitis Panel market estimates and forecast, 2018 - 2030
  • Fig. 75 Lyme Panel market estimates and forecast, 2018 - 2030
  • Fig. 76 UTI Panel market estimates and forecast, 2018 - 2030
  • Fig. 77 Microsatellite Instability market estimates and forecast, 2018 - 2030
  • Fig. 78 B-raf market estimates and forecast, 2018 - 2030
  • Fig. 79 Epidermal Growth Factor Receptor market estimates and forecast, 2018 - 2030
  • Fig. 80 Kirsten rat sarcoma virus market estimates and forecast, 2018 - 2030
  • Fig. 81 Other market estimates and forecast, 2018 - 2030
  • Fig. 82 U.S. molecular diagnostics market: end-use movement analysis
  • Fig. 83 U.S. molecular diagnostics market: end-use outlook and key takeaways
  • Fig. 84 Hospital Core Laboratory market estimates and forecast, 2018 - 2030
  • Fig. 85 Hospital Alternative Sites market estimates and forecast, 2018 - 2030
  • Fig. 86 Decentralized Test Sites market estimates and forecast, 2018 - 2030
  • Fig. 87 Reference Lab market estimates and forecast, 2018 - 2030
  • Fig. 88 Participant categorization- U.S. molecular diagnostics market
  • Fig. 89 Market share of key market players- U.S. molecular diagnostics market